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6/j.bThe outcome of cord blood transplantation following reduced-intensity conditioning is suboptimal because
of fatal infection triggered by prolonged neutropenia and graft-versus-host disease (GVHD) in addition to
graft rejection. Intrabone marrow injection (IBMI) may improve the outcome by providing better hemato-
poietic engraftment and less GVHD. We therefore evaluated IBMI safety in reduced-intensity stem cell
transplantation. Furthermore, we used unwashed cord blood to avoid stem cell loss. Ten patients (median
age 5 61 years old) were enrolled. Cord blood cells were thawed at the bedside and injected into 4 iliac
bone sites (2 at each hemipelvis). The procedure was well tolerated with no injection-related complications.
Nine patients achieved donor engraftment. The median time to neutrophil recovery (.0.5  109/L) was 17
days, and platelet recovery was achieved in 8 patients. Early full donor chimerism was achieved (median of 15
and 20 days in T cells and myeloid cells, respectively). Three of 9 evaluable patients developed grade II to III
GVHD, and 5 of 10 patients died of treatment-related toxicities. The probability of survival at 1 year was
46.7%. IBMI of unwashed cord blood following reduced-intensity conditioning is safe, well tolerated, and
may lead to an increased donor engraftment rate.
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Unwashed cord bloodINTRODUCTION
In recent years, umbilical cord blood transplanta-
tion (CBT) has been increasingly used for adult patients
with hematologic malignancies. The use of reduced-
intensity conditioning (RIC) markedly broadened the
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bmt.2011.08.010HLA-matched sibling donor; however, although the
outcome of CBT for younger patients who have re-
ceived myeloablative conditioning is reportedly similar
to that of patients who have undergone unrelated
bone marrow transplantation [1-5], the outcome of
RIC CBT (RI-CBT) for elderly patients remains
suboptimal [6-9]. In particular, the major drawbacks
of CBT are the high incidence of graft failure and
delayed hematopoietic recovery, both of which are
mainly attributable to the small number of progenitors
infused.
Studies using animal models have suggested that in-
trabone marrow injection (IBMI) of hematopoietic stem
cells promotes engraftment [10-12] and reduces the risk
of graft-versus-host disease (GVHD) [11]. The im-
provement of engraftment conferred by this technique
is likely attributable to the advantage of the seeding effi-
ciency of progenitor cells, which is superior to that of in-
tervenous (i.v.) infusion, where only a small proportion
of progenitor cells engraft bone marrow (BM) [12-14].
Thus, we planned to perform a clinical study of
IBMI of cord blood after RIC treatment. Moreover,
most institutes in Japan, including our transplant
team, routinely use unwashed cord blood for i.v.633
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and to reduce the risks associated with the cell-washing
procedure, such as bacterial contamination, and have
not experienced particular problems. Based on this
previous experience, we planned to use unwashed
cord blood for IBMI. Because the safety of IBMI of
unwashed cord blood containing dimethyl sulfoxide
(DMSO) as a cryoprotectant has not been established
to date, we conducted a phase I study to evaluate the
safety of this procedure.METHODS
Patients
Themajor objective in this study was to evaluate the
safety of reduced-intensity intrabonemarrowCBTusing
unwashed cord blood units. It was planned to enroll
10 patients in this phase I study. The subjects were adult
patients age 55 to 70 years, or younger patients whowere
considered ineligible for myeloablative preparative regi-
mens because of comorbidities. Patients were eligible to
enroll in this study if they required allogeneic stem
cell transplantation and could not be paired with human
leukocyte antigen (HLA)-matched or 1 antigen-
mismatched related donors, or unrelated donors (geno-
typically matching or 1 locus-mismatching in HLA-A,
B, and DRB1 loci) within a clinically useful period of
time. If even 1patient had life-threatening adverse effects
after the infusion of unwashed cord blood, the study
would be discontinued. This protocol was approved by
the institutional review board ofHyogoCollege ofMed-
icine and the ethics committee of the Japan Cord Blood
Bank Network. All patients signed an approved consent
form before participating in the study.
Cord Blood Grafts
A cord blood search was performed through the
Japan Cord Blood Bank Network. All cord blood units
were processed (ie, red blood cells and plasma removed)
and cryopreserved at each of the 11 cord blood banks in
Japan according to theNewYorkBloodCentermethod.
The final volume of each unit was uniformly 25 mL.
HLA-A, -B, and -DR antigens were identified by low-
molecular and thenhigh-resolutionmolecular typingus-
ing polymerase chain reaction (PCR) sequence-specific
primers. A cord blood unit was chosen for patients after
considering the HLA disparity between the donor and
recipient, and the cell dose. Cord blood units had $4
of 6 matches regarding HLA-A, -B, and -DR antigens,
and had a cell dose of $2.0  107 nucleated cells per
kilogram of the recipient’s body weight before freezing.
IBMI Procedure
Each cord blood unit was thawed in a 37C water
bath at the bedside in a clean room, and was collectedinto a 50-mL syringe with a Luer lock just before injec-
tion. Patients were premedicated with hydrocortisone
100mg and hydroxyzine 30minutes before starting the
IBMI procedure. After local anesthesia with 1% lido-
caine, standard BM aspiration needles (16-gauge)
were inserted into the superior–posterior iliac crest
of the patient in the prone position. Two needles
were inserted into each hemipelvis at a distance of 4
to 5 cm, except for 1 patient (No. 8) who received
cord blood at 2 sites on 1 side of the pelvis. The stylet
was removed from the needle, a small volume of BM
fluid was aspirated to confirm that the needle was in-
serted into the BM space, and approximately 6 mL of
the collected cord blood aliquot corresponding to
one-fourth of the total volume was slowly injected
into the BM space. Saline (0.5-1 mL) was subsequently
injected to push the small number of cord blood cells
left in the needle into the BM space. The stylet was re-
attached to the needle in order to avoid the backflow of
cord blood into the needle. This procedure was re-
peated for the remaining aliquots. The patient who re-
ceived cord blood on 1 side of the pelvis received a 12-
mL aliquot at 1 site. The entire IBMI procedure took
20 to 30 minutes from the start of local anesthesia to
the end of injection.
Preparative Conditioning and GVHD
Prophylaxis
The conditioning regimen consisted of fludarabine
(40 mg/m2) for 5 days (day –6 to day –2), cyclop-
hosphamide (50 mg/kg) on day –6, and total body
irradiation 3 Gy on day –1 [8]. GVHD prophylaxis
consisted of cyclosporine A (CsA) and mycophenolate
mofetil (MMF): A continuous infusion of CsA was
started at a dose of 3 mg/kg on day –3 with target
serum concentration of 250 to 450 ng/mL, and MMF
was started at a dose of 15 mg/kg/day (divided into
2 or 3 doses) on day –3 for the first 3 patients and at
a dose of 30 mg/kg/day for the next 7 patients because
2 of the first 3 patients developed severeGVHD.When
patients did not have acute GVHD (aGVHD) by day
30, tapering of CsA and MMF was started: CsA was
tapered over months (approximately 5%-10% per
week) and MMF was tapered over 2 weeks.
Supportive Care
Supportive care was performed as previously
described [15]. In brief, the enrolled patients were
hospitalized in a single room ventilated with a high-
efficiency particulate air filtration system. Each patient
received fluoroquinolones and azoles (fluconazole,
itraconazole, or voriconazole) from the beginning of
the preparative regimen until the discontinuation of
immunosuppressants. In addition, acyclovir was ad-
ministered at a dose of 1000 mg/day for 5 weeks after
transplantation, and was subsequently continued at
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munosuppressants. Patients seropositive for cytomeg-
alovirus received prophylactic ganciclovir (5 mg/kg)
for 5 days during the preparative treatment. Cytomeg-
alovirus pp65 antigenemia was monitored weekly. In
addition, the reactivation of human herpesvirus-6
was monitored biweekly by PCR analysis of the virus
DNA, and was also checked when patients developed
a preengraftment immune reaction. Granulocyte
colony-stimulating factor (300 mg/m2) was started
from day 1 and was continued until the neutrophil
count was .2.5  109/L for 2 consecutive tests.
Chimerism Analysis
The chimerism status of the donor/recipient was
monitored using the T cell– or granulocyte-enriched
cell fraction of the peripheral blood. Themethodology
used for cell separation and chimerism analysis has
been detailed elsewhere [15,16]. T cells were
enriched by a negative selection system (RosetteSep;
StemCell, Vancouver, Canada) to a purity of .95%,
and granulocytes were recovered from the Ficoll–red
blood cell interface with a purity of.99%. Chimerism
analysis involved quantitative PCR of informative
short tandem repeats in the recipient and donor.
Definitions and Statistical Analysis
Engraftment was defined as the first of 3 consecu-
tive days of absolute neutrophil count .0.5  109/L.
Mixed chimerism was defined as between 5% and
95% donor cells, and full donor chimerismwas defined
as the presence of .95% donor cells [17]. Primary
graft failure was defined as the lack of even partial do-
nor engraftment (mixed chimeric status). Secondary
graft failure was defined as a decreased percentage of
donor cells to\5% after achievement of at least mixed
chimerism. Diagnosis of aGVHD and chronic GVHD
(cGVHD) was based on standard clinical criteria [18],
and was pathologically confirmed if possible. Cumula-
tive incidence was used to estimate the rates of neutro-
phil engraftment and platelet recovery, treating
nonevent deaths as a competing risk. Overall survival
(OS) was calculated using the Kaplan-Meier method.
The data were ‘‘locked‘‘ for analysis on December
31, 2010.RESULTS
Patient and Graft Characteristics
Ten patients were enrolled in this clinical study be-
tween June 2008 and June 2010. The patient and graft
characteristics are summarized inTable 1. Themedian
age of the patients was 61 years (range: 51-66 years),
and their median weight was 57.1 kg (range:
43.0-86.3 kg). The diagnoses includedmyelodysplasticsyndrome or acute myeloid leukemia evolved from
myelodysplastic syndrome (n 5 4), acute myeloid leu-
kemia (n 5 2), acute lymphoblastic leukemia (n 5 2),
and non-Hodgkin lymphoma (n 5 2). At the time of
transplantation, 5 patients were in a nonremission sta-
tus, and the remaining 5 were hematologically in com-
plete remission but 4 had minimal residual disease
detected by real-time PCR analysis using the WT1
gene [19] or chimeric genes. Patients received cord
blood cells containing a median of 2.72  107 (range:
2.04-3.50  107/kg) nucleated cells/kg and a median
of 0.60  105 (range: 0.30-0.99  105/kg) CD341
cells/kg.
Safety and Tolerability of IBMI Procedure
No particular adverse events were observed in the
IBMI of cord blood. Injection of cord blood into the
BM space could be performed without resistance.
During injection, the patients did not experience
pain except for some patients who experienced mild
pain during the injection of saline to push cord blood
cells in the needle into the BM space.Moreover, no ab-
normalities were observed in general clinical examina-
tions, including blood pressure, heart rate, and oxygen
saturation.
For the first 7 patients who received 6-mL injec-
tions of cord blood at each IBMI site, a distinct odor
derived from DMSO was imperceptible by the staff
in the individual clean rooms during and after the
injection of cord blood. In contrast, for the eighth pa-
tient who received 12-mL injections of cord blood at
each IBMI site, the DMSO-derived odor was clearly
perceptible in the room. These observations suggest
that a considerable proportion of cord blood cells
injected into the BM came out into the circulation
soon after the 12-mL injection at each BM site; there-
fore, we used 6-mL injections for the remaining 2 pa-
tients, and noted that the DMSO-derived odor was
again imperceptible in their rooms.
Engraftment and Chimerism
One patient (No. 9) showed no signs of neutrophil
recovery, with 100% recipient chimerism on day 24,
and was diagnosed with primary graft failure. The re-
maining 9 patients achieved engraftment: the median
time to reach a neutrophil count of $0.5  109/L
was day 17 (range: 7-33 days), as shown in Figure 1A.
Platelet recovery was achieved in 8 patients, and the
median time to reach a nontransfused platelet count
of $20  109/L and $50  109/L was 41 days (range:
12-55 days) and 43 days (range: 36-103 days), respec-
tively (Table 1, Figure 1A). In the majority of patients
achieving donor engraftment, donor T cell recovery
preceded donor neutrophil recovery (Figure 1B).
Neutrophils increasing in the early period of trans-
plantation were mostly of recipient origin, which
Table 1. Patient Characteristics and Transplant Outcomes
Patient
No.
Age/
Sex
Weight
(kg) Diagnosis
Disease
Status
HLA Disparity Cord Blood Unit Time to recovery (days) Acute GVHD Chronic
Relapse
Current
Status
(Day)
Cause of
Death
GVH
Vector
HVG
Vector
NCC
(107/kg)
CD34
(105/kg)
Neutrophil
$ 0.5 
109/L
Platelet
$ 20 
109/L
Platelet
$ 50 
109/L Skin Gut Liver Grade GVHD
1 64/M 48.4 MDS-AML Untreated 4/6 4/6 3.05 0.88 7 12 39 2 1 0 II Ex — dead (214)† MRSA sepsis
2 58/F 43.0 MDS-AML CR5, MRD+ 4/6 4/6 3.50 0.69 9 — — 3 3 0 III NA — dead (81) TMA
3 60/M 56.5 ALL, Ph+ CR1, MRD+ 5/6 6/6 3.27 0.99 9 42 45 2 0 0 I — — alive (>809) —
4 66/F 47.1 AML, M4 Refractory 5/6 5/6 2.05 0.45 24 55 103 2 0 0 I — — alive (>505) —
5 51/M 62.4 MDS Refractory 5/6 5/6 2.58 0.45 17 35 40 3 1 0 II — — dead (111) CMV pneumonia
6 62/M 66.0 ALL CR1 5/6 5/6 2.71 0.30 33 49 55 2 0 0 I — — dead (291) Aspergillus
pneumonia
7 57/M 86.3 NHL (FL) RR-Auto 4/6 4/6 2.04 0.63 17 40 40 2 0 0 I — — alive (>330) —
8 63/M 70.0 AML, M4 CR2, MRD+ 4/6 4/6 2.24 0.56 21 36 36 1 0 0 I — + (166)* alive (>239) —
9 61/M 57.3 MDS-AML CR1, MRD+ 4/6 4/6 3.00 0.70 — — — NA NA NA NA — — dead (143) GVHD after
second SCT
10 57/M 56.8 NHL (PTCL) Refractory 5/6 5/6 2.72 0.57 17 47 47 3 0 0 II — — alive (>141) —
M indicates male; F, female; AML, acute myeloid leukemia; MDS-AML, AML evolved frommyelodysplastic syndrome; ALL, acute lymphoid leukemia; Ph, Philadelphia chromosome; M4, myelomonocytic leukemia; NHL,
non-Hodgkin lymphoma; FL, follicular lymphoma; PTCL, peripheral T cell lymphoma; MRD, minimal residual disease; CR, complete remission; RR-Auto, refractory relapse after autologous stem cell transplantation;
GVH, graft-versus-host; HVG, host-versus-graft; NCC, nucleated cell dose; NA, not applicable; Ex, extensive type; MRSA, methicillin-resistant Staphylococus aureus; TMA, thrombotic microangiopathy.
Figures in the columns of skin, gut, and liver of acute GVHD indicate the stage of GVHD in each organ.
As GVHD prophylaxis, patient Nos. 1, 2, and 3 received CsA and MMF 15 mg/kg, and the next 7 patients received CsA and MMF 30 mg/kg.
*The number in parentheses indicates the day when the patient had a relapse.
†The number in parentheses indicates survival days after transplantation.
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Figure 1. (A) Hematopietic recovery. Solid and broken lines indicate
cumulative incidence of neutrophil recovery $0.5  109/L and unsup-
ported platelet recovery $20  109/L, respectively. (B) Cumulative in-
cidence of achieving full donor chimerism in T (solid line) and myeloid
(broken line) cells of the peripheral blood, respectively.
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some extent: recipient neutrophil counts peaked 0.15
to 1.30 109/L between days 7 and 11, then decreased,
and recipient neutrophils were rapidly displaced with
donor neutrophils. It took a median of 15 days (range:
13-108 days) to achieve full donor T cell chimerism
and a median of 20 days (range: 17-70 days) to achieve
full donor myeloid chimerism.
Outcomes
Patient outcomes are also summarized in Table 1.
The majority of patients achieving donor engraftment
developed preengraftment immune reactions; how-
ever, no particular treatments were needed. Two
(Nos. 1 and 2) of the 3 patients who received CsA
and MMF 15 mg/kg as GVHD prophylaxis developed
grade II and III GVHD, respectively, ultimately re-
sulting in fatal complications of methicillin-resistant
Staphylococcus aureus sepsis or thrombotic microangi-
opathy. Among the remaining 6 evaluable patients
who received CsA and MMF 30 mg/kg, 4 had grade
I GVHD and 2 had grade II GVHD. All patients
achieving donor engraftment developed skin GVHD,
4 gut GVHD, and none hepatic GVHD. Of note, allof these patients responded to a small dose of prednis-
olone. No patients developed chronic GVHD except
for 1 patient (No. 1).
Overall, 5 of the 10 patients died from treatment-
related toxicities: 3 from infection, 1 from thrombotic
microangiopathy, and 1 from GVHD after a second
transplantation. Although 1 patient (No. 8) relapsed
166 days after transplantation, he achieved complete
remission again by receiving salvage chemotherapy.
Five of the 9 patients who achieved donor engraftment
are alive at a median follow-up of 392 days (range:
203-871 days). The probability of OS at 1 year after
transplantation was 46.7%.DISCUSSION
In the present study, we demonstrated that IBMI
using unwashed cord blood was safe and well tolerated.
In addition, the fact that 9 of the 10 recipients achieved
donor-type engraftment suggested that this IBMI
procedure coupled with a RIC treatment had suffi-
cient ability to obtain donor engraftment. Recently,
Frassoni et al. [20,21] reported the outcome of 32
patients treated by IBM-CBT, the majority of whom
received a myeloablative conditioning treatment (in-
cluding 2 patients receiving RIC). Their study also
showed that the IBMI procedure was safe, with the ob-
servation of a high engraftment rate, early and robust
platelet recovery, and a low incidence of aGVHD.
More recently, Brunstein et al. [22,23] reported the
outcome of 10 patients who underwent double-unit
CBT after myeloablative conditioning, in which
1 unit was injected into the BM and the other into
the vein. Although Brunstein et al. [22,23] also
showed the safety of the IBMI procedure, they could
not observe any superiority of IBMI over i.v. infusion.
In the present study, first, we demonstrated that
unwashed cord blood was safely used in the IBMI pro-
cedure. In many transplant centers, cord blood units
are washed before transplantation, according to
a method previously reported by Rubinstein et al.
[24]. The 2 aforementioned IBMI studies of cord
blood also used washed cord blood. Removal of
DMSO may reduce the incidence of adverse reactions
associated with the infusion of DMSO [25,26];
however, the clinical implications of cell washing are
arguable because a much greater amount of DMSO
is routinely infused with autologous peripheral blood
stem cell products and, more important, cell washing
may lead to the loss of cells to be transplanted. Of
note, Barker et al. [27] reported a high engraftment
rate in CBT using a simplified method of diluting
thawed cord blood with albumin-dextran. Our proce-
dure of IBMI using unwashed cord blood is a particu-
larly simple method that could be conveniently
completed at the bedside, although the method might
638 Biol Blood Marrow Transplant 18:633-639, 2012M. Okada et al.not be applied to cord blood units of much larger vol-
ume, such as cord blood units without plasma reduc-
tion.
Even though the aim of the present study was not to
evaluate the efficacy of IBMI, better donor engraftment
may be expected with this transplant procedure because
9 of the 10 patients achieved donor engraftment with
early achievement of full donor chimerism; however,
because of the small number of patients treated, we
have not yet determined whether this IBMI procedure
using unwashed cord blood produces early hematopoi-
etic recovery or a high rate of donor engraftment com-
pared with the usual i.v. infusion methods. Several
RI-CBT studies using i.v. infusion methods showed
that the platelet recovery rate (platelet count $20 
109/L or $50  109/L) varied from 42% to 80%
[6,8,9,28]. In the present study, platelet recovery
occurred in 80% of the patients. This favorable
platelet recovery after IBMI is consistent with the
results reported by Frassoni et al. [20], but not by
Brunstein et al. [22,23], in which only 5 of 10 patients
achieved platelet recovery. Regarding the volume of
cord blood injected at each BM site, we and Frassoni
et al. [20] injected a small aliquot (4-6mL) of cord blood
at each site, whereas Brunstein et al. [22,23] injected
a large volume of 20 mL into each site. In order to
assess the efficacy of IBMI with cord blood accurately,
as many cells as possible should be retained in the BM
after injection; however, there is no accurate method
at present to assess how many cells are retained.
Interestingly, as described by Brunstein et al. [22] who
used washed cord blood, we also noticed the distinct
odor of DMSO in 1 patient who received a 12-mL in-
jection at each site, which strongly suggested that a sub-
stantial number of cord blood cells immediately entered
the bloodstream with DMSO and that DMSO was no-
ticed in expiratory air from the lungs; however, with
other patients who received a 6-mL injection at 1 injec-
tion site, the DMSO-derived odor was imperceptible in
their rooms. This observation suggests that the volume
of cord blood injected at eachBM sitemay be important
in IBM-CBT, which may explain the difference in he-
matopoietic recovery between the studies by Frassoni
et al. [20] and Brunstein et al. [22], although a difference
in the strength of preparative regimens can affect en-
graftment, as shown by Barker et al. [6]; however, deliv-
ering hematopietic stem cells to the BM site might not
be sufficient to explain any observed advantages of in-
trabone transplantation if the BM and circulatory sys-
tem are closely connected. In this regard, Feng at al.
[29] reported that intrabone injection facilitated BM
homing and redistribution to noninjection-side BM
cavities through enhanced expression of cell adhesion
molecules on donor cells.
Regarding the occurrence of GVHD, 2 of the first
3 patients in our study who received MMF 15 mg/kg/
day as GVHD prophylaxis developed severe aGVHDthat ultimately led to transplant-related deaths. The
dose of MMF 15 mg/kg may have been too low to
obtain a clinically effective blood concentration of
the agent. The subsequent 6 evaluable patients who re-
ceived MMF at an increased dose of 30 mg/kg daily,
which was the same dosage as used by Frassoni et al.
[20,21], still developed preengraftment immune
reactions, and 2 had grade II GVHD; however, it is
of note that GVHD occurring in these patients was
easily controlled with a small dose of steroid, and
none developed cGVHD.
In conclusion, the present study demonstrated the
safety of IBMI using unwashed cord blood in a trans-
plant setting of RIC. A larger-scale clinical study is
required to determine whether IBMI has advantages
in hematopoietic recovery or the risk of GVHD. We
are planning to proceed to a multicenter, phase II
study to evaluate the efficacy of IBM-CBT.ACKNOWLEDGMENTS
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